A Retrospective Comparative Study of Clinicopathological Features in High-Grade and Low-Grade Serous Ovarian Carcinoma
DOI:
https://doi.org/10.22487/htj.v11i1.1558Keywords:
High-grade serous carcinoma, Low-grade serous carcinoma, ClinicopathologyAbstract
Backgroud: Ovarian carcinoma is the third most common malignancy in Indonesian women after breast and cervical cancer. Serous ovarian carcinoma is the most frequent subtype, divided into low-grade and high-grade types, each with distinct genetic and biological characteristics. Objective:
This study aims to compare the clinicopathological features of high-grade and low-grade serous ovarian carcinoma. Methods: A retrospective cross-sectional study was conducted using 77 paraffin-embedded samples of serous ovarian carcinoma. Clinical and pathological data including age, body mass index (BMI), age at menarche, and parity were collected and analyzed using the chi-square test. Results: Patients aged >50 years accounted for most cases, with 64.3% presenting high-grade serous carcinoma (HGSC). Overweight/obesity was observed in 40.3% of cases. Early menarche (<13 years) was reported in 78%, and 42.7% were multiparous. No significant differences were found in clinical variables between HGSC and low-grade serous carcinoma (LGSC). Histopathologically, HGSC showed more pronounced cytologic atypia, necrosis, and metastasis. Conclusion: High-grade serous carcinoma demonstrates greater aggressiveness compared to its low-grade counterpart. Histopathological assessment plays a critical role in diagnosis, treatment decisions, and prognosis evaluation.
References
Miyagawa C, Nakai H, Otani T, et al. Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging. J Gynecol Oncol. 2023;34(4):e47. doi:10.3802/jgo.2023.34.e47
Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668-679. doi:10.1038/nrc4019
Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basic of Disease. 10th ed. Elsevier; 2020.
Board WC of TE. Female Genital Tumours. 5th ed. World Health Organization; 2020.
American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society. Published online 2022.
Lisio MA, Fu L, Goyeneche A, Gao Z hua, Telleria C. High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. IJMS. 2019;20(4):952. doi:10.3390/ijms20040952
Wandira NA, Dinengsih S, Novelia S. Analysis of Ovary Cancer in the Gynecology Room. MIDPRO. 2023;15(1):166-179. doi:10.30736/md.v15i1.506
Solikhah S, Perwitasari D, Rejeki D. Geographic Characteristics of Various Cancers in Yogyakarta Province, Indonesia: A Spatial Analysis at the Community Level. Asian Pac J Cancer Prev. 2022;23(4):1231-1238. doi:10.31557/APJCP.2022.23.4.1231
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Intl J Gynecology & Obste. 2021;155(S1):61-85. doi:10.1002/ijgo.13878
Goldblum JR, Lamps LW, McKenney JK. Rosai and Ackerman’s Surgical Pathology. Elsevier; 2017.
Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. Williams Gynecology. 3rd ed. McGraw Hill/Medical; 2016.
Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type i and type II. BioMed Research International. 2014;2014(1). doi:10.1155/2014/934261
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Healthy Tadulako Journal (Jurnal Kesehatan Tadulako)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.